AUTHORS
Juan-Jose Garces, PhD, Holly Lee, MD, PhD2, Ross Firestone, MD/PhD3, Ozgur Can Eren, MD, PhD4, Bachisio Ziccheddu5, Christine Riedhammer6, Jan Frenking, MD7, Kevin Herrera8, Kylee Maclachlan, MD, PhD9, Jesús Gutiérrez-Abril, PhD10, Sarun Sereewattanawoot, MD, PhD11, Carlyn Rose Tan, MD12, Kevin Han13, Eric L Smith, Director of Translation, Immune Effector Cell Therapies14, Paola Neri, MD, PhD15, Benjamin Gabriel Barwick, PhD16, Vikas Gupta, MD, PhD17, Lawrence H Boise, PhD18, Ahmet Dogan, MD19, Issam Hamadeh20, Marc-Steffen Steffen Raab, MD21, Leo Rasche Jr, MD22, Michael J Kluk23, Nizar Bahlis, MD24, Karlo Perica25, Sham Mailankody, MBBS26, Saad Z. Usmani, MD27, Francesco Maura, MD28
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 University Hospital Würzburg, Würzburg, Germany
7 Heidelberg University Hospital, Heidelberg, Germany
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Dana Farber Cancer Institute, Boston, United States
15 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
16 Emory University, Atlanta, United States
17 Emory University, Atlanta, United States
18 Emory University, Atlanta, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Heidelberg University Hospital, Heidelberg, Germany
22 University Hospital Würzburg, Würzburg, Germany
23 Memorial Sloan Kettering Cancer Center, New York, New York, United States
24 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
25 Memorial Sloan Kettering Cancer Center, New York, New York, United States
26 Memorial Sloan Kettering Cancer Center, New York, New York, United States
27 Memorial Sloan Kettering Cancer Center, New York, New York, United States
28 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Background: Anti-GPRC5D CAR T-cell therapies and T-cell engagers have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM), with overall response rates of 70–80%. However, a subset of patients exhibit primary refractoriness, with biological mechanisms underlying this resistance remaining largely unknown.
Methods: We analyzed whole-exome sequencing (WES), whole-genome sequencing (WGS), and RNA sequencing data from the 549 newly diagnosed multiple myeloma (NDMM) patients enrolled in the MMRF CoMMpass study to identify patients with low GPRC5D expression. Clinical validation was performed in two independent RRMM cohorts: (1) 24 patients treated with investigational anti-GPRC5D CAR-T therapies (NCT04555551, NCT05431608) and (2) 139 patients treated with Talquetamab (TAL). GPRC5D protein expression was assessed using a newly developed, fully automated, immunohistochemistry (IHC) assay on pretreatment bone marrow (BM) biopsies from 24 CAR-T-treated patients and 45 TAL-treated patients. GPRC5D protein expression was quantified using a semiquantitative IHC scoring system ranging from 0 to 3+. An IHC score of 0 was classified as negative, 0-1+ as low expression, 1 and 1-2+ as intermediate expression and ≥2+ as high expression. All IHC scoring was performed independently by two hematopathologists.
Results: Low GPRC5D RNA expression was observed in 54/549 (9.8%) NDMM patients in the CoMMpass dataset. This is in striking contrast with TNFRSF17 (BCMA) and FCRL5 which are highly expressed by virtually all NDMM. Among these, only 16.4% (9/54) harbored GPRC5D deletions, which were typically large and always monoallelic. Patients with low GPRC5D expression were significantly enriched for t(11;14) (p<0.0001) and displayed Cyclin D2 (CD2)-like gene expression programs characteristic of B-cell–like myeloma (Gupta et al., Blood 2021).
To validate the clinical impact of low GPRC5D expression, we assessed 24 RRMM patients treated with anti-GPRC5D CAR-T therapy by IHC. Four patients were classified as negative or low expressors. All but one of these patients harbored t(11;14) and had poorer progression-free survival (PFS) and universal primary refractoriness (p<0.001). To further evaluate the association between t(11;14) GPRC5D-negativity and B-cell likeness, we repeated BM IHC in a cohort of 32 RRMM patients with t(11;14) treated with BCL2 inhibitors. Consistent with CoMMpass findings, patients with GPRC5D negativity showed marked sensitivity to BCL2 inhibition with dramatically improved PFS (median PFS NR vs 173 days, p=0.0067). One additional case included a patient with t(11;14) and GPRC5D-negativity by IHC who developed tumor lysis syndrome after a single 100 mg dose of Venetoclax. Another GPRC5D-negative patient with primary resistance to anti-GPRC5D CAR-T therapy subsequently achieved a prolonged complete remission lasting four years with Venetoclax.
In the TAL cohort (n=139), the presence of t(11;14) alone did not have a statistically significant association with PFS (p=0.19). Negative or low GPRC5D expression by IHC was observed in 19/43 evaluable patients. None of these patients responded to TAL, and all progressed or deceased within the first 6 months of follow-up, resulting in significantly inferior PFS compared with the remainder of the cohort (p<0.0001). Negative/low GPRC5D expression remained an independent predictor of poor outcome after adjustment for extramedullary disease and number of prior lines of therapy in multivariable analysis. The t(11;14) B-cell–like subtype is typically associated with a more indolent disease course and is underrepresented among patients treated in later lines, such as the TAL-treated population. Accordingly, only 6/19 patients with negative/low GPRC5D expression harbored t(11;14).
Conclusions: This study identifies a previously unrecognized population of MM patients with absent or low GPRC5D expression prior to any GPRC5D-directed therapies. Importantly, we establish a clinic-ready IHC-based assay to identify these GPRC5D negative/low patients who are both unlikely to benefit from anti-GPRC5D therapies and exquisitely sensitive to BCL2 inhibitors. Negative/low GPRC5D expression represents a simple and reproducible biomarker that may guide therapy selection in MM, particularly as these approaches move into earlier lines of therapy.
DISCLOSURES
Juan-Jose Garces, PhD: Menarini Group - Consultancy (Includes expert testimony)